Skip to main content
Erschienen in: Clinical Pharmacokinetics 15/2004

01.12.2004 | Original Research Article

A Standard Weight Descriptor for Dose Adjustment in the Obese Patient

verfasst von: Dr Stephen B. Duffull, Michael J. Dooley, Bruce Green, Susan G. Poole, Carl M. J. Kirkpatrick

Erschienen in: Clinical Pharmacokinetics | Ausgabe 15/2004

Einloggen, um Zugang zu erhalten

Abstract

Objective

To develop a standard weight descriptor that can be used for estimation of patient size for obese patients.

Patients and methods

Data were available from 3849 patients: 2839 from oncology patients (index data set) and 1010 from general medical patients (validation data set). The patients had a wide range of age (16–100 years), weight (25–165kg) and body mass index (BMI) [12–52 kg/m2] in both data sets. From the normal-weight patients in the oncology data set, an equation for male and female patients was developed to predict their normal weight as the sum of the lean body mass and normal fat body mass. The equations were evaluated by predicting the weight of patients in the general medical data set who had a normal BMI (<25 kg/m2). In addition, the clinical utility of the predicted normal weight (PNWT) descriptor was assessed by (i) comparing body surface area and allometric scaling calculations based on actual weight of obese patients versus PNWT; and (ii) comparing the predictive performance of creatinine clearance using the Cockcroft and Gault equation when using actual weight of obese patients versus PNWT to predict gentamicin clearance.

Results

The PNWT equations developed from the oncology data set predicted accurately the actual weight of normal weighted (BMI <25 kg/m2) general medical patients (R2 = 0.968 men, R2 = 0.946 women). Using actual weight when computing body surface area and when allometric scaling for obese patients results in significant overestimation of patient size, especially for female patients and those with BMIs >35 kg/m2. The use of PNWT in the Cockcroft and Gault equation provided better predictions of gentamicin clearance than when using actual weight.

Conclusions

A standard weight descriptor has been developed that can be used in dosing algorithms for patients who are obese (BMI >30 kg/m2).
Literatur
1.
Zurück zum Zitat Cheymol G. Clinical pharmacokinetics of drugs in obesity: an update. Clin Pharmacokinet 1993; 25: 103–14PubMedCrossRef Cheymol G. Clinical pharmacokinetics of drugs in obesity: an update. Clin Pharmacokinet 1993; 25: 103–14PubMedCrossRef
2.
Zurück zum Zitat Georges C. Effects of obesity on pharmacokinetics. Implications for drug therapy. Clin Pharmacokinet 2000; 39: 215–31CrossRef Georges C. Effects of obesity on pharmacokinetics. Implications for drug therapy. Clin Pharmacokinet 2000; 39: 215–31CrossRef
3.
Zurück zum Zitat Dooley MJ, Singh S, Poole SG, et al. Distribution and discordance of body surface area (BSA) and body mass index (BMI) in 4514 patients with malignancy: the utility of BMI to identify obese patients and its implications in BSA adjusted dosing of cytotoxics [abstract]. Proc Am Soc Clin Oncol 2002; 21: 356 Dooley MJ, Singh S, Poole SG, et al. Distribution and discordance of body surface area (BSA) and body mass index (BMI) in 4514 patients with malignancy: the utility of BMI to identify obese patients and its implications in BSA adjusted dosing of cytotoxics [abstract]. Proc Am Soc Clin Oncol 2002; 21: 356
4.
Zurück zum Zitat Devine B. Case study number 25: gentamicin therapy. Drug Intel Clin Pharm 1974; 8: 650–5 Devine B. Case study number 25: gentamicin therapy. Drug Intel Clin Pharm 1974; 8: 650–5
5.
Zurück zum Zitat James W. Research on obesity. London: Her Majesty’s Stationary Office, 1976 James W. Research on obesity. London: Her Majesty’s Stationary Office, 1976
6.
7.
Zurück zum Zitat Green B, Duffull SB. Caution when using lean bodyweight as a size descriptor for obese subjects. Clin Pharmacol Ther 2002; 72: 743–4PubMedCrossRef Green B, Duffull SB. Caution when using lean bodyweight as a size descriptor for obese subjects. Clin Pharmacol Ther 2002; 72: 743–4PubMedCrossRef
8.
Zurück zum Zitat Anastasio P, Spitali L, Frangiosa A, et al. Glomerular filtration rate in severely overweight normotensive humans. Am J Kidney Dis 2000; 35: 1144–8PubMedCrossRef Anastasio P, Spitali L, Frangiosa A, et al. Glomerular filtration rate in severely overweight normotensive humans. Am J Kidney Dis 2000; 35: 1144–8PubMedCrossRef
9.
Zurück zum Zitat Nowack R, Raum E, Blum W, et al. Renal hemodynamics in recent-onset type II diabetes. Am J Kidney Dis 1992; 20: 342–7PubMed Nowack R, Raum E, Blum W, et al. Renal hemodynamics in recent-onset type II diabetes. Am J Kidney Dis 1992; 20: 342–7PubMed
10.
Zurück zum Zitat DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863–71CrossRef DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863–71CrossRef
11.
Zurück zum Zitat Mosteller RD. Simplified calculation of body surfaced area [letter]. N Engl J Med 1987; 22: 1098 Mosteller RD. Simplified calculation of body surfaced area [letter]. N Engl J Med 1987; 22: 1098
12.
13.
Zurück zum Zitat Felici A, Verweij J, Sparreboom A. Dosing strategies for anti-cancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002; 38: 1677–84PubMedCrossRef Felici A, Verweij J, Sparreboom A. Dosing strategies for anti-cancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002; 38: 1677–84PubMedCrossRef
14.
Zurück zum Zitat Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590–611PubMed Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590–611PubMed
15.
Zurück zum Zitat Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 335–9CrossRef Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 335–9CrossRef
16.
Zurück zum Zitat Duffull SB, Kirkpatrick CMJ, Begg EJ. Comparison of two Bayesian approaches to dose-individualisation for once-daily aminoglycoside regimens. Br J Clin Pharmacol 1997; 43: 125–35PubMedCrossRef Duffull SB, Kirkpatrick CMJ, Begg EJ. Comparison of two Bayesian approaches to dose-individualisation for once-daily aminoglycoside regimens. Br J Clin Pharmacol 1997; 43: 125–35PubMedCrossRef
17.
Zurück zum Zitat Kirkpatrick CMJ, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999; 47: 637–43PubMedCrossRef Kirkpatrick CMJ, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999; 47: 637–43PubMedCrossRef
18.
Zurück zum Zitat Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41PubMedCrossRef Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41PubMedCrossRef
19.
Zurück zum Zitat Pesola GR, Akhavan I, Madu A, et al. Prediction equation estimates for creatinine clearance in the intensive care unit. Intensive Care Med 1993; 19: 39–43PubMedCrossRef Pesola GR, Akhavan I, Madu A, et al. Prediction equation estimates for creatinine clearance in the intensive care unit. Intensive Care Med 1993; 19: 39–43PubMedCrossRef
20.
Zurück zum Zitat Gusella M, Toso S, Ferazzi E, et al. Relationships between body composition parameters and fluorouracil pharmacokinetics. Br J Clin Pharmacol 2002; 54: 131–9PubMedCrossRef Gusella M, Toso S, Ferazzi E, et al. Relationships between body composition parameters and fluorouracil pharmacokinetics. Br J Clin Pharmacol 2002; 54: 131–9PubMedCrossRef
21.
Zurück zum Zitat Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003; 56: 96–103PubMedCrossRef Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003; 56: 96–103PubMedCrossRef
22.
Zurück zum Zitat Fisher DM, Reynolds KS, Schmith VD, et al. The influence of renal function on the pharmacokinetics and pharmacodynamics and simulated time course of doxacurium. Anesth Analg 1999; 89: 786–95PubMed Fisher DM, Reynolds KS, Schmith VD, et al. The influence of renal function on the pharmacokinetics and pharmacodynamics and simulated time course of doxacurium. Anesth Analg 1999; 89: 786–95PubMed
Metadaten
Titel
A Standard Weight Descriptor for Dose Adjustment in the Obese Patient
verfasst von
Dr Stephen B. Duffull
Michael J. Dooley
Bruce Green
Susan G. Poole
Carl M. J. Kirkpatrick
Publikationsdatum
01.12.2004
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 15/2004
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200443150-00007

Weitere Artikel der Ausgabe 15/2004

Clinical Pharmacokinetics 15/2004 Zur Ausgabe

Acknowledgement

Acknowledgement